OBJECTIVE: To examine whether grip strength, gait speed, and the combination of the two physical functioning measures modified the association of systolic BP (SBP) and diastolic BP (DBP) with mortality. DESIGN: Nationally representative cohort study. SETTING: Health and Retirement Study. PARTICIPANTS: 7,492 U.S. adults aged ≥65 years. MEASUREMENTS: Grip strength was measured by a hand dynamometer and classified as normal (≥16 kg for female; ≥26 kg for male) and weak. Gait speed was assessed over a 98.5-inch walk and classified as non-slow (≥0.60 m/s for female; ≥0.52 m/s for male) and slow. RESULTS: Over an average follow-up time of 6.0 years, 1,870 (25.0%) participants died. After adjustment for socio-demographic, behavioral, and clinical measures, elevated SBP (≥150 mmHg) and DBP (≥90 mmHg) was associated with a 24% (95% CI, 7-43%) and 25% (95% CI, 5-49%) higher mortality among participants with normal grip strength. In contrast, elevated SBP and DBP was associated with a 6% (95% CI, 31 to À27%) and a 16% (95% CI, 46 to À26%) lower mortality among those with weak grip strength (P-values of interactions: both=.07). The inverse relations between BP with death were most pronounced among slow walkers with weak grip strength. The HRs of elevated SBP and DBP for death was 0.85 (95% CI, 0.56-1.29) and 0.53 (95% CI, 0.30-0.96), respectively, and was substantially different from non-slow walkers with normal grip strength (HR = 1.24 and 1.15, respectively; P-values of interactions: both <.001). Therefore, associations of BP with death varied modestly by gait speed. CONCLUSION: Grip strength modified the association of BP with death. Combination of grip strength and gait speed has incremental value for modifying the association of BP with death.
O lder adults represent the fasting growing age group in the U.S. and have the highest prevalence of hypertension. 1 Although the majority of evidence points toward an increase in cardiovascular morbidity and mortality among persons with high blood pressure (BP), the findings are less clear among some populations of older adults, especially frail/low-functioning persons or the very old. There has been a large body of epidemiological evidence showing low BP is associated with increased risk of cardiovascular (CV) events, poor physical and cognitive functions, and mortality in elders; [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] whereas other studies have reported elevated BP remains to be a risk factor for CV outcomes and mortality in old age. 12, 13 Moreover, findings from randomized controlled trials (RCTs) are mixed with regard to the benefits of antihypertensive treatment in reducing mortality among older adults; [14] [15] [16] [17] [18] [19] [20] the optimal treatment for hypertension in this age group remains controversial. [21] [22] [23] [24] [25] Reasons for these differences in the association of high BP with death among elders are largely unknown. One explanation is substantial heterogeneity exists in health status among older adults; there may exist subgroups of elders who are not at increased risk for high BP-related death. We have previously demonstrated the association of high BP with mortality was attenuated in low-functioning elders, characterized by slow gait speed at usual pace. 26, 27 However, whether other functional measures modify this relationship is less well known. Grip strength, an indicator of overall body strength, is an ideal alternative marker. 28 Grip strength is a key component of frailty, and is associated with cognitive decline, disability, and mortality. [29] [30] [31] [32] Moreover, grip strength is frequently available in epidemiological studies and can be conveniently assessed by a simple and inexpensive device in the clinical setting.
We examined whether grip strength and gait speed modified the associations of systolic BP (SBP) and diastolic BP (DBP) with mortality among older adults. Based on existing findings, 26, 27, [33] [34] [35] [36] [37] [38] we hypothesized that higher SBP and DBP would be each associated with increased mortality among adults with normal functional status, but these associations would be attenuated in low-functioning ones. We also investigated the incremental value of grip strength in combination with gait speed in identifying older adults who are not at increased risk of high BP-related mortality.
METHODS

Study Design
The Health and Retirement Study (HRS) is a populationbased cohort study of a nationally representative sample of non-institutionalized adults aged ≥51 years in the U.S. The HRS was launched in 1992 and had assessments on health conditions, financial situation, and employment status every other year thereafter. In Wave 2006, approximately 50% of the participants were randomly selected to participate in an enhanced face-to-face interview, during which BP, physical function, and blood-based biomarkers were measured. The other half of the sample completed the functional measures and biomarkers in Wave 2008. The University of Michigan Institutional Review Board approved the study protocol. Further details about the recruitment strategies, study designs, and sampling approaches of the HRS have been documented elsewhere. 39 
Participants
We used pooled data from the 2006 and 2008 waves. The sample was restricted to 7,500 participants who (1) aged ≥65 years; (2) had ≥1 BP reading obtained in a sitting position with full compliance; (3) completed grip strength and gait speed measures; and (4) had mortality information. Eight participants with extreme gait speed (>2.0 m/s) were further excluded.
Outcome
The outcome was all-cause mortality. Vital status and date of death were ascertained based on a variable that recorded participants' year and month of death taken from the respondent's exit interview or the spouse/partner's interview. Mortality status was ascertained through April 2015. Participants were censored when lost to follow-up or the end of the analytic period (April 2014).
Predictors
Trained interviewers using automated sphygmomanometer measured BP. Three BP readings, 45-60 seconds apart, were taken in a sitting position with both feet on the floor and the left arm supported with the palm facing up. 40 The average of the readings was calculated.
Effect Modifiers
Grip strength (kg) was measured by a spring-type hand dynamometer. Participants were asked to squeeze the meter at their maximum capacity in a standing position twice for each hand. The average of readings for dominant hand was calculated. For participants who reported having equally strong hands, the higher average was used. Based on clinically relevant cut-points suggested by Alley et al., 41 a grip strength <16 kg for female and <26 kg for male was classified as "weak" (2014). Gait speed was calculated by converting the amount of time required to walk 98.5 inches (%2.5 meters) at usual pace into meter per second. Two trials were conducted, and the average was calculated. We used the lowest quintile of the sample distribution as cut-point to classify slow (<0.52 m/s for female; <0.60 m/s for male) and non-slow walkers.
Covariates
Demographics included age, sex, race (white, non-white), and education (<high school, high school, >high school). Behavioral characteristics included smoking status (current, former, never), and body mass index (BMI) defined as body weight (kilograms) divided by height (meters) squared. Clinical measures included total cholesterol, high-density lipoprotein (HDL) cholesterol, glycosylated hemoglobin (HbA1c), C reactive protein (CRP), and cystatin C; missing clinical measures were imputed using the last-observation-carried-forward approach. Chronic conditions including cardiac disease, stroke, cancer (excluding skin cancer), diabetes (assessed by self-report, medication use, or insulin use), lung disease, and arthritis and antihypertensive medication use (yes, no) were self-reported.
Statistical Analysis
We first compared participants across grip strength and gait speed (separately) using a chi-squared test for categorical variables and a t-test for continuous variables. We estimated the mortality rates across grip strength (weak vs normal) and gait speed (slow vs non-slow); we then calculated the risk difference in persons with and without elevated BP (≥150 mmHg for SBP; ≥90 mmHg for DBP) across grip strength and gait speed.
We used Cox models 42 to estimate the association of SBP and DBP (separately) with mortality. SBP and DBP were modeled both as continuous variables (per 10-mmHg) and in categories (<150 and ≥150 mmHg for SBP; <90 and ≥90 mmHg for DBP). 22 Demographics, behavioral measures, clinical measures, medical history, and antihypertensive medication were included as covariates in adjusted models. We used robust standard errors to account for the nested data structure of the HRS.
To evaluate effect modification, we included interactions between grip strength and gait speed and elevated BP and used a Wald test for interaction. We then stratified the models by categories of grip strength and gait speed. The joint effect of grip strength and gait speed was examined by entering the terms for the combination of grip strength and gait speed; we used a global test for interaction to examine whether the association of BP with death varied by functional status.
We conducted several sensitivity analyses. First, we evaluated the association of BP with mortality by functional status, excluding deaths that occurred in the first 2 years of follow-up (n = 413). Additionally, we repeated the analyses with a different cutoff for defining elevated SBP (≥140 mmHg). Lastly, because not completing the physical function test may be an indicator of low functional status, we examined the association of BP with morality among participants who did not complete the walk and grip strength tests due to reasons other than logistical (separately). All analyses were performed using Stata 13.1. 43 
RESULTS
Participant Characteristics
Over an average follow-up time of 6.0 years, 1,870 participants died; the mortality rate was 41.5 per 1,000 personyears (PYs). A total of 1,077 (15.9%) participants were classified as "weak" in grip strength. The average BP levels for participants with weak and normal grip strength were 133.3 and 134.5 mmHg (SBP), and 76.1 and 76.8 mmHg (DBP), respectively (Table 1) . Participants with weak grip strength were older, less likely to be male, had fewer years of education than those with normal grip strength. Persons with weak grip strength also had higher prevalence of a history of cardiac disease, stroke, diabetes, cancer, lung disease, arthritis, and antihypertensive medication. Participants with the lowest physical function (weak grip strength and slow gait speed) were older and more likely to be women, had higher prevalence of chronic conditions than those with either normal grip strength or non-slow gait speed or both (Table S1 ). They also had lower levels of total cholesterol and HDL cholesterol and higher levels of cystatin C and CRP.
Association of BP with Mortality Across Grip Strength
Mortality rates were 35.4 and 85.4 per 1,000 PYs among participants with normal and weak grip strength, respectively. Among those with weak and normal grip strength, the differences in mortality rates between SBP ≥150 and <150 mmHg were 9.3 and 14.7 per 1,000 PYs, respectively ( Table 2 ). The difference in mortality rate between DBP ≥90 and <90 mmHg was 2.4 per 1,000 PYs for persons with normal grip strength, whereas weak participants with high DBP (≥90 mmHg) had a lower mortality rate (À9.8 per 1,000 PYs).
There is suggestive evidence that the association of high SBP (≥150 mmHg) and mortality differed across grip strength; P-values of interactions for unadjusted and adjusted models were .03 and .07, respectively. After multivariable adjustment, higher SBP was associated with a 24% higher mortality among persons with normal grip strength (P < .01). In contrast, SBP was not associated with mortality among weak participants; the HR was 0.94 (95% CI, 0.69-1.27). The adjusted HR for high DBP (≥90 mmHg) was 1.25 (95% CI, 1.05-1.49) among participants with normal grip strength, whereas weak participants with high DBP had a lower mortality risk, although the relation was not significant (HR, 0.84; 95% CI, 0.56-1.26). P-values of interactions for unadjusted and adjusted models of DBP were .26 and .07, respectively. We did not find that higher BP was associated with lower mortality among 225 non-completers of the grip strength test (Table S2) .
Association of BP with Mortality Across Gait Speed
The differences in mortality rates between SBP ≥150 and <150 mmHg were 9.1 and 13.4 per 1,000 PYs for slow and non-slow walkers, respectively (Table S3) . Slow walkers with elevated DBP had a lower mortality rate (À3.4 per 1,000 PYs), whereas the difference in mortality rate between DBP ≥90 and <90 mmHg was 0.7 per 1,000 PYs among non-slow walkers. After multivariable adjustment, the HR of higher SBP (≥150 mmHg) for death was not significantly higher among slow walkers, whereas higher SBP was associated with a significantly higher mortality among non-slow walkers (HR, 1.17; 95% CI, 1.00-1.38); P-value for interaction = .36. The association of DBP with mortality did not vary substantially by gait speed. An inverted relationship was observed between elevated SBP and mortality among 483 non-completers of the walk test due to non-logistical reasons (Table S3) .
Association of BP with Mortality across the Combination of Grip Strength and Gait Speed
We investigated the joint effect of grip strength and gait speed with the reference being normal grip strength and non-slow gait speed. The associations of SBP and DBP with death varied by functional status (P-values of global tests for interactions <.001). Among slow walkers with weak grip strength (poor functioning; n = 458, 6.1%) and non-slow walkers with normal grip strength (usual functioning; n = 5,375, 71.7%), the mortality associated with elevated SBP was 0.85 and 1.24, respectively ( Table 3) . The mortality related to elevated DBP among slow walkers with weak grip strength was much lower than those who had non-slow gait speed and normal grip strength (HR = 0.53 vs 1.15).
Sensitivity Analyses
Results were robust against sensitivity analyses where participants who died within the first 2 years were excluded. The association of elevated SBP and DBP with death differed between participants with low and normal grip strength; P values for interactions were .02 and .01, respectively (Table 4 ). In contrast, the associations were not significantly modified by gait speed. The inverse relation between BP and death was most pronounced among participants having weak grip strength and slow gait speed ( Figure 1 ). Additionally, results did not change substantially when elevated SBP was defined based on an alternative cut-point (≥140 mmHg) (Table S4) .
DISCUSSION
In this nationwide cohort study of 7,492 U.S. older adults, we found grip strength modified the association of BP with death. Specifically, among elders with normal grip strength (≥16 kg for female; ≥26 kg for male), elevated SBP (≥150 mmHg) and DBP (≥90 mmHg) were associated with increased mortality risk, whereas there were no significant relationships among those with weak grip strength. However, evidence is less consistent for gait speed. Moreover, we found that the inverse associations of BP with mortality were most pronounced among participants with weak grip strength and slow gait speed. Our findings are consistent with prior studies showing that the association of high BP with CV events and mortality was attenuated or inverted in elders with poor functional status. 26, 27, [33] [34] [35] [36] 38 We extended previous research by examining the role of grip strength, an indicator of overall body strength and physical function, 28 in the association of BP with death. Our findings suggest, compared to gait speed, grip strength may be a better marker of functional status in identifying subgroups of older adults in whom low BP is potentially beneficial. Previous investigations into gait speed as an effect modifier of the association of BP with outcomes have been mixed. While majority of evidence points towards a gait speed as a strong effect modifier, one previous study reported no effect modification by gait speed. Peralta et al. 34 found that the association of BP with cardiovascular disease or death varied by limitation in performing activities of daily living but not by gait speed among adults aged ≥75 years (2014). One reason for this inconsistency could be the variation of assessment of usual gait speed (e.g., distance, walking surface). [44] [45] [46] It is also possible that other factors (e.g., habit, motivation) may influence gait speed, or that different measures may better capture effect modification across different populations. Interestingly, we found that elevated SBP was associated with a lower mortality in non-completers of the walk test, which is consistent with previous findings. 26 Walk test requires coordination of multiple physiological systems and missing data on the walk test may be an indicator of a low level of overall functional status. In contrast, we did not find an inverse relation between BP with mortality among non-completers of the grip strength test. One explanation is missing data on the grip strength test may be an indicator for hand impairment rather than a reduced level of overall health, and therefore a poor surrogate for functional status. However, special caution is needed to interpret these results because there was a wide range of non-logistical reasons for not completing the test, precluding us from drawing definite conclusions.
In addition to examining the independent role of grip strength and gait speed in the relation between BP and death, we investigated two measures jointly. The association of low BP with higher mortality was most pronounced Adjusted for age, sex, race (white, non-white), years of education, smoking status (current, former, never), body mass index, antihypertensive medication, stroke, cardiac disease, cancer, diabetes, high-density lipoprotein cholesterol, total cholesterol, cystatin C, glycosylated hemoglobin, and C reactive protein.
f P for global test of the interaction term <.001.
g P for global test of the interaction term <.001. *P < .05, **P < .01, ***P < .001. Grip strength ≥16 kg for female and ≥26 kg for male.
c Adjusted for age, sex, race (white, non-white), years of education, smoking status (current, former, never), body mass index, antihypertensive medication, stroke, cardiac disease, cancer, diabetes, high-density lipoprotein cholesterol, total cholesterol, cystatin C, glycosylated hemoglobin, and C reactive protein. *P < .05, **P < .01, ***P < .001.
among slow walkers with weak grip strength. These findings suggest combination of grip strength and gait speed has incremental value for identifying low-functioning elders who are not at increased risk of high BP-related mortality. Functional status is a multidimensional construct encompassing functional capacity, performance, reserve, and capacity utilization. 47 Combining grip strength with gait speed, which capture different aspects of functional status, may better assess functional status and identify low-functioning persons compared to either measure alone.
The mechanisms by which functional status modifies the relation between high BP and death are not well understood. One possible explanation is, among elders with declined functional status, high BP is important for maintaining adequate perfusion of vital organs such as heart and brain, 24, 36, 48 which may prevent increased risk of CV and cerebrovascular events. Several lines of evidence support this explanation. Sabayan et al. found higher SBP was associated with lower risk of incident stroke among cognitively impaired elders (2012). 28 Peralta et al. showed that elevated DBP was related to a reduced risk of incident CV events (2014). 34 Another explanation for the null association of BP with mortality among low-functioning adults is that low BP can be a marker for the end of life. However, the data suggest this is not plausible because similar patterns of association were observed when excluding persons who died within the first 2 years of follow-up.
Strengths of this study include a large, heterogeneous cohort of non-institutionalized elders, availability of multiple physical functioning measures, a relatively long followup period, and detailed data on demographic, behavioral, and clinical covariates. We acknowledge several limitations. First, we only used the baseline levels of BP and functional measures; these measures may vary over time, leading to misclassification. In addition, although we adjusted for a wide range of confounders, residual confounding could still exist. RCTs may minimize this unavoidable bias in observation studies. However, elderly patients in trials are selective due to stringent exclusion criteria; trial results may not be generalizable to the general elderly population. Recently, Bress et al. 49 showed that only 19.5% of U.S. adults aged 60-74 years and 34.6% aged ≥75 years were eligible for the Systolic Blood Pressure Intervention Trial (SPRINT) (2016). A treatment de-intensification trial, where patients receive either standard treatment or a less intensive one, may provide a better understanding of the association of BP with mortality among low-functioning older adults, who are not well represented in clinical trials. Moreover, we focused on the modifying effects of two markers of physical function. However, we understand that the association of low BP with higher risk of unfavorable outcomes has also been observed among elders with impaired cognitive function 35, 36 and older patients with more advanced vascular age. 48, 50, 51 Future research needs to evaluate whether combination of different markers of physical, cognitive, and vascular age could better identify elders who are vulnerable to low BP. In a nationwide cohort of U.S. older adults, physical function measures modified the association of BP with death. The inverse associations of BP with mortality were most pronounced among participants with weak grip strength and slow gait speed. Findings are relevant to antihypertensive treatment decisions because findings of the SPRINT may result in more aggressive interventions among the general elderly population, which includes lowfunctioning elders. Moreover, our findings may further advance precision medicine, which emphasizes the importance of tailoring medical decisions and practices to individuals based on their genetic signature, clinical characteristics, and functional status.
ACKNOWLEDGMENTS
An abstract of this study was presented at the Society for Epidemiologic Research, Miami, FL, 2016.
Conflict of Interest: The authors have no conflicts of interest.
Financial Disclosure: This study was supported by National Institute on Aging (K01AG039387, R01AG46206).
Authors' Contributions: Study concept and design: CW, CAP, MCO. Analysis and interpretation of data: CW, ES, MCO. Subject matter expertise: CAP, HS, MCO. Preparation, revision, and approval of manuscript: CW, ES, CAP, HS, MCO. Chenkai Wu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Please note: Wiley-Blackwell is not responsible for the content, accuracy, errors, or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
